on evidence from "real-world" studies 7, 8 and meta-analyses. 9 Patient willingness and compliance as well as physician adherence and compliance may impact on outcomes. 10, 11 The aim of this analysis was to explore the differences in outcomes between VKA "new starters" and "switchers" in patients with nonvalvular AF. We performed a post hoc ancillary analysis using pooled individual patient data from two randomized, open-label trials (AMADEUS and BOREALIS), with negligible subjective intention of switching between OACs and trial-adjudicated outcomes.
| ME THODS
The full details of the designs of the AMADEUS and BOREALIS trials have been described previously, and are summarized in Supplemental Methods. 12, 13 The AMADEUS and BOREALIS trials were approved by the institutional review boards and all patients provided written informed consent. Patients from the VKA arms were categorized into two groups according to their treatment after randomization, that is, "VKA new starters" (on VKA and without previous VKA treatment) or "VKA switchers" (on VKA and with previous VKA treatment).
| Study endpoints
In this pooled analysis, we included all outcomes collected from the initiation of the treatment to the end of the studies. The primary analysis of the both trials reported only outcomes collected during the on-treatment period. The primary efficacy outcome of this analysis was the composite of stroke and systemic thromboembolism (SE). Stroke was further classified into ischemic and nonischemic stroke based on brain imaging results. SE was confirmed by angiography, surgery, or autopsy in the original trials. The primary safety outcome was major bleeding, as defined on previously published criteria. 12, 13 Other efficacy outcomes of venous thromboembolism, myocardial infarction, and safety outcomes of any clinically relevant bleeding, intracranial hemorrhage, were defined according to the original trials. 12, 13 All-cause death and the subgroups of fatal stroke and cardiovascular death were also assessed in this analysis. 12, 13 Only the first event of each outcome and their occurrence date were used for analysis. Suspected outcome events in both trials were adjudicated by each independent central adjudication committee that was blinded to the treatment assignment.
| Statistical analysis
Baseline characteristics were reported as percentages or mean ± SD. In the "VKA new starters" group, there were significantly more females, and paroxysmal AF, prevalent hypertension, left ventricular dysfunction, coronary artery disease concomitant aspirin, clopidogrel, or ticagrelor use. "VKA new starters" had significantly lower body mass index, creatinine clearance, and TTR ( Table 1 ).
| RE SULTS
The characteristics of the patients by AMADEUS and BOREALIS datasets were not different to the pooled analysis (Table SI) .
| Efficacy and safety outcomes
"VKA new starters" had higher crude rates of all-cause mortality (P = .036) and cardiovascular death rates (P = .047) compared to "VKA switchers" (Table SII) .
On multivariable Cox regression analysis, with "VKA switchers" used as reference, "VKA new starters" had nonsignificant risks of stroke/SE, major bleeding, and all-cause death in Model I and Model II (Figure 1 ). Kaplan-Meier survival curves did not show significant difference in stroke/SE (P = .09), major bleeding (P = .28), and all-cause mortality (P = .06) between the two groups ( Figure 2 ).
| D ISCUSS I ON
In this ancillary analysis of the AMADEUS and BOREALIS trials, VKA "new starters" had a nonstatistically significant risk of stroke/SE and similar rates of major bleeding and all-cause death compared with VKA "switchers", after adjusting for associated comorbidities and risk factors. This is contrary to the perception that "new starters" and "switchers" were patients at higher risk of adverse outcomes. 
TA B L E 1 (Continued)
need to be carefully assessed. 14 Relatively lower effectiveness and safety of "switchers" from VKA to NOACs compared to NOAC "new starters" have been reported, and have questioned whether the switching to NOACs is a marker of poor adherence and higher comorbidity. 8, 10, 15, 16 As patients were randomly allocated to the study groups in the randomized trials, these concerns on adherence and comorbidities are reduced in the current analysis.
One previous study, 16 mimicking a randomized study using a marginal structural model analysis, pointed out that no other bleeding risk except for gastrointestinal bleeding risk increased in patients who switched from VKA to dabigatran. The above results were broadly consistent with the large randomized trial with dabigatran, the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) clinical trial. 3 Subsequently, results of the RE-LY trial were the basis of dabigatran approval by FDA. 17 Previous "real-world" studies suggested that the benefits appeared to be decreased in NOAC switchers, with the assumption of poor compliance or residual confounding from comorbidities among NOACs switchers. 9, 10 In the present ancillary pooled analysis of AMADEUS and BOREALIS trials on a group of VKA-treated patients only, those who were VKA starters had similar risks of stroke/SE, major bleeding, and all-cause death compared with VKA switchers. The main difference of the present study compared with previous comparisons lies in the fact that there was no drug switching, but not whether they had prior VKA treatment history before their strict trial-related follow-up. This meant that F I G U R E 2 Nelson-Aalen cumulative hazard ratios of stroke/SE, major bleeding, and all-cause death. SE, systemic thromboembolism; VKA, vitamin K antagonists benefits were not reduced and risks were not increased by prior VKA treatment history.
One point worth mentioning is that the higher risk of all-cause mortality rates in "VKA new-starters" was caused by higher burden of cardiovascular diseases. One possible reason could be that they were more likely to take antiplatelet agents (aspirin, clopidogrel) as their first antithrombotic choice, but not warfarin before randomization. However, this significant difference disappeared after multivariate adjustment.
| Switchers and starters from randomized trials
Studies are considered as having loss of precision if they only focus on new users in the evaluation of comparative effectiveness. 18 In contrast, bias is increased by confounding in studies mainly focused on switchers. Randomized trials were composed of both starters and switchers in the two different trials at randomization, but this balance would be disrupted if comparisons were performed between switchers and starters within drugs. Indeed, previous unadjusted meta-analysis of VKA arms of randomized trials showed an increased risk of thromboembolism in VKA starters compared to VKA switchers. 19 Two Cox regression models were therefore used to improve the accuracy of comparisons; subsequently, our analysis showed that switchers did not show any inferiority of effectiveness or safety in the two comparison settings (VKA switchers vs VKA new starters). Although new starters had an increased burden of cardiovascular diseases, leading to higher cardiovascular and all-cause death rates, the safety and efficacy were not significantly different after multivariate adjustment.
| Limitations
There are several limitations for this study. First, this study lacked information of control quality of previous warfarin use and international normalised ratio (INR) values in bridging, 14 though labile INR was not the reason for the drug switching and switching between VKAs in both trials was without subjective intention. Also, we recognize some differences in clinical characteristics between the two patient groups; nonetheless, these were adjusted in our Cox Model
II. Second, information on anticoagulation bridging treatment (if any)
was unavailable for both studies, which made us unable to provide information whether the current results were associated with overlapped treatment or switching interval. Also, we did not have information on the OAC previously used in VKA switchers. Nevertheless, the negative results from the comparisons between VKA switchers and new starters help clarify their similar safety profile.
| CON CLUS IONS
In this post hoc analysis of clinical trial patients with AF, "new starters" and "switchers" for VKA initiation had nonstatistically significant rates of trial-adjudicated outcomes of thromboembolism, major bleeding, and all-cause mortality. This is contrary to the perception of healthcare professionals that "new starters" and "switchers" were patients at higher risk of adverse outcomes.
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